LLY stock news · Eli Lilly and Company
Get alerts for LLY
Follow Eli Lilly and Company (LLY) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for LLYLilly Endowment plans to sell 295,000 shares of Eli Lilly worth about $405.24 million.
NeutralLilly Endowment plans to sell 295,000 Eli Lilly shares after cutting its holding since August. This is a shareholder sale, not a change to Lilly's business, so its outlook is unchanged.
Eli Lilly's CEO Dave Ricks answered doubts about new medicines, while Elon Musk praised the company's future drugs.
NeutralEli Lilly's CEO publicly backed the company's ability to innovate, and Elon Musk praised upcoming drugs. The exchange shares confidence, not new results, so it does not change Lilly's outlook.
OmniAb shared its third-quarter results, showing revenue growth and a big deal with Eli Lilly.
NeutralLilly joined OmniAb on a new ion-channel discovery program, but the call reports no change in Lilly's sales, costs, or results from the program. It does not show a changed outlook for Lilly.
Eli Lilly 'Deserves' Stock Upside: Analyst
Good for LLYEli Lilly beat analysts' sales and profit estimates and raised its 2026 sales plan, despite trimming its profit range. The results favor the company.
RBC Capital Markets increased its price target for Eli Lilly to $1,600, up from $1,500.
Good for LLYRBC raised its price target for Eli Lilly after praising its third-quarter results and kept its Outperform rating. The update points to a more positive view of the company.
Truist raised its price target for Eli Lilly to $1,612 from $1,376 and still recommends buying.
Good for LLYTruist raised its price goal for Eli Lilly and kept its Buy rating. That signals a more hopeful view of the shares, though the story adds no new company results.
JPMorgan has set a new price goal of $1,650 for Eli Lilly, showing more faith in its future earnings.
Good for LLYJPMorgan raised its Eli Lilly target and sales and profit forecasts, citing its metabolic business and weight-loss drug pipeline. The report supports a brighter outlook for Lilly.
Eli Lilly's stock reached a new high as the CEO said more middle-income families want weight-loss drugs.
Good for LLYLilly said broader demand for its weight-loss medicines and Medicare coverage helped improve its forecast by about $10 billion. Sales growth and room to reach more patients support a positive reading.
Big investors are making moves in 10 health care stocks today.
NeutralThe alert marked Eli Lilly's call trade bullish. It reports trading activity, not a company change, so it does not change Eli Lilly's outlook.
Big investors are making moves with 9 health care stocks today.
NeutralEli Lilly was listed with a put trade labeled bearish. This reports options activity, not a change in the company’s business, so it does not change its outlook.
The Energy sector dropped on Tuesday while safer areas like Health Care and Financials did well.
NeutralEli Lilly shares rose 4.68% as Health Care led the sectors. The report gives no company news, so the session does not change its outlook.
Roche has stopped future investments in Germany because of a disagreement about drug price cuts.
Bad for LLYEli Lilly cut its planned German manufacturing investment by half. That reduces its planned expansion in Germany, making this news unfavorable for the company.
JD Vance praises TrumpRx for lowering drug prices, calling it a win for American jobs before the midterms.
NeutralEli Lilly is named in hidden TrumpRx pricing contracts, but the story gives no financial details. It does not show a change to Lilly's business outlook.
Eli Lilly's GLP-1 pill gets important support in Europe for helping with obesity and diabetes.
Good for LLYEli Lilly received a European committee’s recommendation for its pill for diabetes and weight management. The reported benefits make this encouraging, though final marketing permission is not reported.
New ETF from REX Shares focuses on the growing peptide market, not just Eli Lilly and Novo Nordisk.
NeutralA new peptide ETF spreads investment across many companies, and the article cites growing drug demand. It reports no change to Lilly's business, so Lilly's outlook is unchanged.
Stephen King criticizes Trump’s new press secretary for her old posts about vaccines and election claims.
NeutralThe story mentions Eli Lilly’s recent share rise but reports no new company development or link between the dispute and Eli Lilly’s business.
Today, big investors are making moves with 10 health care stocks.
NeutralEli Lilly's put trade was labeled neutral. The report gives no new company result or plan, so it does not change the company's outlook.
Eli Lilly shared details from its call about money made in the second quarter of 2026.
Good for LLYLilly said Q2 revenue rose 48% from Q2 2025, raised its full-year forecast, and gained wider Medicare coverage for obesity medicines. The report points in a positive direction.
The drug industry is suing the Trump administration, saying the new Medicare drug pricing rule is illegal and unfair.
NeutralPhRMA sued to block a Medicare drug-pricing rule, but Lilly is among companies CMS plans to exempt. The rule is expected to reach few drugs, leaving little clear change for Lilly.
The Dow dropped more than 300 points as bond rates jumped, leaving investors feeling uncertain.
NeutralEli Lilly rose 2.7% as Morgan Stanley kept its positive rating, but the story adds no new business results or deal details, so it does not change Lilly’s outlook.
Today, big trades were spotted in 4 health care stocks.
NeutralLLY had a call option trade described as having a positive view. The article reports no new business results, so this alone does not change Lilly's outlook.
The FDA has now allowed Eli Lilly's treatment for use in adults with untreated leukemia.
Good for LLYThe FDA approved Lilly's Jaypirca for first-line use in a defined group of adults with leukemia. Study results support a wider role for the drug, making this positive for Lilly.
Foghorn Therapeutics is changing its plans after ending its partnership with Eli Lilly.
NeutralLilly and Foghorn will stop work on 2 joint drug programs. The report does not say this changes Lilly's wider business outlook.
Foghorn Therapeutics Inc. says it will spend money to close down some operations.
NeutralEli Lilly and Foghorn will not take FHD-909 into the trial's expansion phase, and further work under their partnership is not expected. The filing gives no effect on Lilly's other work or finances, so it does not change the company outlook.
Chuck Schumer criticizes the Hyde Amendment on its 50th birthday, saying it makes people pick between health care and basic needs.
NeutralEli Lilly announced a plan to widen access to its diabetes and obesity treatments. The story reports no business results from the plan, so it does not change the company's outlook.